Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 8/20 | 0.55 |
| ▸ | PSMB5 | P28074 | 8/20 | 0.55 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | LTA4H | P09960 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL871366 | 0.99 | LTA4H (0.54) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL237631 | 0.93 | HRH3 (0.58) | HRH3 | |
| SCHEMBL18824777 | 0.92 | HRH3 (0.56) | HRH3 | |
| SCHEMBL18844624 | 0.89 | HRH3 (0.52) | HRH3 | |
| SCHEMBL1367081 | 0.89 | LTA4H (0.52) | HRH3LTA4HKDM4E | |
| SCHEMBL171775 | 0.88 | ALDH1A1 (0.55) | PSMB1PSMB5HRH3LTA4HKDM4E | |
| SCHEMBL29602879 | 0.87 | PSMB1 (0.43) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL25301027 | 0.87 | LTA4H (0.41) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL12435690 | 0.86 | LTA4H (0.41) | PSMB1PSMB5PSMB2HRH3LTA4H | |
| SCHEMBL22137694 | 0.86 | HRH3 (0.50) | PSMB1PSMB5PSMB2HRH3LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | UNIV MASARYKOVA (CZ) | 2025-11-20 | — | — | US | disclosed |
| EP-4602046-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | Masarykova Univerzita (CZ) | 2025-08-20 | — | — | EP | disclosed |
| WO-2025064853-A1 | RIPK3 INHIBITORS AND METHODS OF USE | Momentum Therapeutics, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2025-03-20 | — | — | US | disclosed |
| CN-118126036-A | 7-Azaindole compound and preparation method and application thereof | 复旦大学 | 2024-06-04 | — | — | CN | disclosed |
| WO-2024078649-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | MASARYKOVA UNIVERZITA (CZ) | 2024-04-18 | — | — | WO | disclosed |
| EP-4353727-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | Masarykova Univerzita (CZ) | 2024-04-17 | — | — | EP | disclosed |
| US-RE47731-E1 | Kinase inhibitors and method of treating cancer with same | UNIV HEALTH NETWORK (CA) | 2019-11-19 | — | — | US | disclosed |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2019-07-23 | — | — | US | disclosed |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2018-10-04 | — | — | US | disclosed |
| US-20140045822-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
| US-8481533-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481525-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY OF HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2012-10-18 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| EP-2417127-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | University Health Network (CA) | 2012-02-15 | — | — | EP | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2010115279-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092031-A1 | RIPK3 INHIBITORS AND METHODS OF USE | RIPK3, RIPK1, RIPK2 | PSMB1 2919/4885PSMB5 3419/4885PSMB2 2353/4885 |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PSMB1 3921/4885PSMB5 2928/4885PSMB2 3632/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | PSMB1 3705/4885PSMB5 2894/4885PSMB2 3460/4885 |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PSMB1 3921/4885PSMB5 2928/4885PSMB2 3632/4885 |
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | FLT3, ROS1, MAP4K2 | PSMB1 4167/4885PSMB5 3571/4885PSMB2 3513/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PSMB1 3921/4885PSMB5 2928/4885PSMB2 3632/4885 |
| US-10358436-B2 | Kinase inhibitors and method of treating cancer | MAP3K6, MAP3K5, MAP3K19 | PSMB1 3921/4885PSMB5 2928/4885PSMB2 3632/4885 |
| US-20140045822-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | PSMB1 3705/4885PSMB5 2894/4885PSMB2 3460/4885 |
| US-20180282306-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PSMB1 3921/4885PSMB5 2928/4885PSMB2 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.